Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes.
Nutriband’s proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is working with Kindeva Drug Delivery to complete the scale-up of the commercial manufacturing process for AVERSA Fentanyl. The two companies started with a feasibility agreement and have since entered a commercial-development and clinical-supply agreement aimed at manufacturing product for a planned human-abuse potential clinical study, which is crucial for the New Drug Application (“NDA”) that the company anticipates submitting to the U.S. Food and Drug Administration. “AVERSA aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles,” said the company in the press release. “The AVERSA technology is supported by a robust intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico and Australia. . . . The AVERSA(TM) trademark is integral to Nutriband’s platform technology, which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential.”
To view the full press release, visit https://ibn.fm/UWiO1
About Nutriband Inc.
Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) technology. This technology can be integrated into any transdermal patch to prevent the abuse, misuse, diversion and accidental exposure of drugs with abuse potential. For more information about the company, please visit www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN